Similar data on costs and utilisation between users of insulin lispro, a human insulin analogue with an improved action profile over regular human insulin, have been shown possibly because of an additional glucose control improvement with no increase or decrease in the number of SH episodes in patients with type 1 diabetes, showing similar or lower diabetes-related and total medical costs as a result of fewer inpatient hospital expenditures (16–18). This evidence concerns the gene INS and diabetes mellitus.